Drugs Used in Gynecology

Authors

  • Rehan Haider Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan.
  • Zameer Ahmed Dow University of Health Sciences, Karachi, Pakistan.
  • Sambreen Zameer Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
  • Geetha Kumari Das Pharmaceutical Inc., OPJS University, Rajasthan, India.

DOI:

https://doi.org/10.33687/ricosbiol.03.01.0044

Keywords:

Gynecology, Hormonal therapy, Oral contraceptives, Menstrual disorders, Endometriosis, Polycystic ovary condition (PCOS), Fertility situations, Antimicrobial powers, NSAIDs, SERMs, Aromatase inhibitors, Intrauterine devices (IUDs), Menopause, Dysmenorrhea, Women's Health

Abstract

Gynecology surrounds a roomy range of medical environments and physiologic states specific to the female generative order, necessitating miscellaneous pharmacological attacks. This review surveys the classifications, mechanisms of operation, and dispassionate applications of drugs secondhand in gynecology. Hormonal medicines, including spoken contraceptives, progestin, and gonadotropin-clearing birth control method (GnRH) agonists, address conditions like menstrual irregularities, endometriosis, and polycystic ovary disease (PCOS). Fertility situations such as clomiphene citrate, letrozole, and gonadotropins mark ovulation inference.Antimicrobial agents treat contaminations like bacterialvaginosis and pelvic angering disease.Nonsteroidal antiangering drugs (NSAIDs) and rising therapies, to a degree discriminating estrogen receptor modulators (SERMs) and aromatase inhibitors, contributeto pain administration and birthcontrolmethodrelated gynecologicalcancers. Patientparticular determinants, containing comorbidities, age, and reproductive aims, are critical in optimizing thesituation. This review focuseson the diversity and complicatedness of gynecological pharmacology, stressing its importance in fixing daughters' health and history

Downloads

Download data is not yet available.

Author Biographies

  • Rehan Haider, Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan.

    Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan.

  • Zameer Ahmed, Dow University of Health Sciences, Karachi, Pakistan.
    Assistant Professor, Dow University of Health Sciences, Karachi, Pakistan.
  • Sambreen Zameer, Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
    Associate Professor, Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
  • Geetha Kumari Das, Pharmaceutical Inc., OPJS University, Rajasthan, India.

    Pharmaceutical Inc., OPJS University, Rajasthan, India.

References

1 American Diabetic Association. Consensus happening colloquium on insulin fighting, November 1998. Diabetic Care. 1997;21:310-4.

2 American Society for Reproductive Medication. Revised 2003 Consensus on demonstrative tests and unending electricity dangers had a connection with polycystic ovary situation. Fertil Steril. 2003;18:19-25.

3Aziz R, Ehrmann D, Legro RS, Witcomb R, and others. Troglitazone develops ovulation and hirsutism in polycystic ovary condition: A multicenter, double-blind, fake tablet-reserved trial. J Clin Endocrinol Metab. 2001;86:1626-32.

4Begum MR, Quadir E, Begum A, and others. Position of aromatase prevention in ovulation initiation in inmates accompanying susceptible solution to clomiphene citrate. J Obstet Gynecol Res. 2006;32:502.

5Berning B, Bennink CHJT, Fauser BCJM. Tibolone and charm belongings on cartilage: An evaluation. Climacteric. 2001;4:120-36.

6Burghen GA, Givens JR, Judd HL, Kaplan SA. Correlation of hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980;50:113-6.

7Cardone V, GnRH antagonists for the situation of PCOS. Fertil Steril. 2003;80:525-31.

8Carmina E, Lobo RA. Polycystic ovaries in hairy ladies accompanying sane period. Am J Med. 2001;111:602-6.

9Chang RJ, Nakamura RM, Judd JL, Kaplan SA. Insulin opposition in non-corpulent sufferers accompanying polycystic ovarian discomfort. J Clin Endocrinol Metab. 1983;57:113-6.

10Chrousos GP. The gonadal hormones and inhibitors. In Katzung BG (Ed.). Basic and scientific Pharmacology. 9th ed. worldwide version: McGraw Hill; 2004:678-9.

11Daga S, Gunby J. Recombinant towards urinary FSH for ovarian provocation in helped duplication levels. (Cochrane overview in the Cochrane Library, trouble 1, 2001). Oxford: replace software program.

12Delta P, and others. Spectroscopic and chromatographic evidence of NADPH cruel placental extract secondhand as wound therapist. J Pharm Biomed evaluation. 2004;34(five):1091.

13Delmas PD, Bjarnason NH, Mitlak BH, and others. Consequences of raloxifene on cartilage now not organic bulk, antitoxin cholesterol concentrations, and uterine endometrium in postmenopausal daughters. N Engl J Med. 1997;337:1641-7.

14Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy consequence between daughters accompanying polycystic ovary condition acted accompanying metformin. Hum Reprod. 2002;17:2858-64.

15Gorden SF. Scientific taking place accompanying a seven-epoch estradiol transdermal scheme for estrogen substitute remedy. Am J Obstet Gynecol. 1995;173(2):998.

16Greenblatt RB, Roy S, Mahesh VB, and others. Am J Obstet Gynecol. 1962;84:1445-51.

17Haspells AA. Emergency delivery manipulates: A overview. Contraception. 1994; 50:101-08.

18Hosking D, Chilvers CE, Christiansen C, and others. Prevention of cartilage misfortune accompanying alendronate in postmenopausal daughters under 60 age adult. N Engl J Med. 1998;338:485-92.

19Kolibianakis E, Bourganic C, Albano C, and others. Effect of ovarian provocation accompanying recombinant FSH, GnRH foe, and HCG on endometrial development at the epoch of oocyte boost. Fertil Steril. 2002;78:1025.

20Lahti E, Blanco G, Kaupilla A, and others. Endometrial modifications in the postmenopausal sense of right and wrong tumor sufferers taking tamoxifen. Obstet Gynecol. 1993;81:660-4.

Further Reading References

21Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE (Eds). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Tenth ed. NY: McGraw Hill; 2001:1597-634.

22Mah PM, Webster J. Hyperprolactinemia: Etiology, sickness, and management. Semin Reprod Med. 2002;20(4):365-74.

23Mahesh VB, Greenblatt RB. Steroid secretions of the rational and polycystic ovary. Latest Prog Horm Res. 1964;20:341-ninety four.

24 Mahesh VB, Greenblatt RB, Aydar CK, Roy S. Secretion of androgens apiece polycystic ovary and allure meaning. Fertil Steril. 1962;13:513-30.

25Moore RA. Livial: An overview of dispassionate research. Br J Obstet Gynecol. 1999;106(19):1.

26Norton PA, Zinner NR, Yalcin I, and others. Duloxetine vs faux tablet within the state of affairs of strain urinary debauchery. Am J Obstet Gynecol. 2002;187(1):40.

27Notelavtz M. Scientific incidence accompanying a 7-epoch estrogen patch: ideas and exercise. Gynecol Endocrinol. 1998;12:249.

28Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic surrendering determinants. In: Hardman JG, Limbird LE (Eds). Goodman and Gilman’s The Pharmacological Foundation of Therapeutics. 10th ed. Big Apple: McGraw Hill; 2001:1552-sixty two.

29Roy S, Greenblatt RB, Mahesh VB, Jungck EC. Clomiphene citrate: further notes of charm used in the inference of ovulation in the human and on attraction fad of operation. Fertil Steril. 1963;14:575-95.

30Saxena P, Salhan S, Sarda N. Sublingual towards the vaginal course of misoprostol for cervical ripening superior to surgical stop of first-trimester gestation. Eur J Obstet Gynecol Reprod Biol. 2006;1(225):109.

31Shibasaki T, and others. Corticotrophin launches determinant-like enterprise merciless placental extract. J Clin Endocrinol Metab. 1982;55(2):384.

32Shohan Z, Patel A, Jacobs HS. Polycystic ovary situation and allure management. J Clin Endocrinol Metab. 2001;86:1626-32.

33Shukla VK, and others. Non-restorative wounds: A restoration disaster. Int J decreases Extremity Wounds. 2003;2(1):40.

34Sur TK, and others. Anti-angering and antiplatelet series movement of human placental extract. Acta Pharmacol Sinica. 2003;24(2):187.

35Verhelst J, Abs R. Hyperprolactinemia: Pathophysiology and management. Treat Endocrinol. 2003;2(1):23-32.

36Vollenhoven BJ, Healy DL. Short and entire assets of ovulation initiation. Endocrinol Metab Clin North Am. 1998;27:903-14.

37Walsh BW, Kuller LH, Wild RA, and others. Effects of raloxifene on antitoxin lipids and clotting determinants in athletic postmenopausal women. JAMA. 1998;279:1445-fifty one.

38Wang CF, Gemzell C. The usage of human gonadotropins for initiation of ovulation in daughters accompanying polycystic ovarian soreness. Fertil Steril. 1980;33:479-86.

39Warren MP, Shantha S. Use of progesterone in dispassionate exercise. Int J Fertil Womens Med. 1999;44(2):96.

40Wilson AC, Meethal SV, Bowen R, and others. Leuprolide acetate: A drug of numerous dispassionate requests. Expert Opin Investig capsules. 2007;16(11):1851.

41Yuzpe AA. Postcoital pregnancy prevention. Clin Obstet Gynecol. 1984;11787-nine.

RBJ

Downloads

Published

20-01-2025

Issue

Section

Research Articles

Categories

Similar Articles

11-20 of 58

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)